news
26.10.09
Green Biologics make it into the Cleantech Connect 2009 Top 30 List
Green Biologics Ltd (GBL) has been listed in the prestigious Cleantech Connect 2009 Awards Top 30 List. The Cleantech Connect 2009 Award recognizes Europe’s most promising and fastest growing cleantech companies and is recognised by the industry as covering the best known and most promising companies in the cleantech industry. The Awards take place on the 18th November where the Cleantech Connect judge companies based on revenue growth and identify “ones to watch”.
Sean Sutcliffe CEO said “We are delighted by the recognition given by inclusion of Green Biologics in the Cleantech Connect Top 30. GBL has continued to develop an international presence by providing innovative bio-process solutions for butanol. The technology produces environmentally friendly and sustainable biofuels with significant potential for GHG reduction. GBL continues to invest in technology development to drive the cost of production down further, enabling butanol as a leading next generation biofuel.”
11.09.09
Green Biologics Expands in China
Green Biologics continues to expand its business in China, based on the success of its strategy of working with the new generation of biobutanol producers established in China. As part of this strategy Green Biologics is introducing its improved technology to these plants to radically reduce the cost of biobutanol production.
"China is a key market for Green Biologics" commented Sean Sutcliffe, Chief Executive. "Not only is it a substantial market in its own right, but by working with the existing producers to improve their financial viability we can rapidly demonstrate our technology to potential clients around the world."
To support this expansion programme GBL has recently expanded its team on the ground with the appointment of Dr. Jin Hou as technical coordinator for the region. Dr. Hou is a Microbiologist with a PhD in Molecular Microbiology and Metabolic Engineering, from Shandong University State Key Laboratory for Microbial Technology. Dr. Hou will coordinate GBL's research collaborations in China and spearhead the technical team working with Chinese commercial partners in demonstrating and establishing GBL's fermentation technology. Jin will be based in Jinan, (Shandong Province) where she will work alongside Charles Xu, GBL's commercial representative in China.
Fergal O'Brien, VP Commercial Operations said “We are delighted to have Jin on our team in China alongside Charles; her appointment is a key part of our commercialisation strategy in China. Having such a capable technologist on the ground to work with customers will enable us to accelerate technology roll out and growth in China."
01.06.09
Professor Zhihao Sun joins GBL as a Scientific Advisor
Zhihao Sun is a Professor at the School of Biotechnology and Principal Investigator at the Biocatalysis Laboratory, Jiangnan University, China. His research focuses on improvements to the continuous butanol fermentation and production of a variety of organic acids and fine chemicals by microbial transformation.
Prior to joining Jiangsu in 1986, Professor Sun worked as a Chief Engineer in the butanol fermentation industry (Sichuan, China) for twenty years. He is widely regarded as an expert on the butanol fermentation process and recently published two review articles detailing the history and recent progress on the butanol fermentation in China.
Sean Sutcliffe, CEO comments: "We are honoured that Professor Sun is joining the Green Biologic's team. He is leading authority on the Chinese ABE process and brings a wealth of practical "hands on" process experience that will help us commercialise our advanced fermentation technology".
01.03.09
Dr Gerald Chan joins Board as Non Executive Director
Green Biologics (GBL) is delighted to announce that Dr Gerald Chan has joined the Board of GBL. This appointment comes alongside the completion of an investment round to continue the development of GBL's commercialization programme, in which Morningside participated alongside existing investors including Oxford Capital Partners and Carbon Trust Investments.
Dr Andrew Rickman, Chairman, commented, "We are delighted to welcome Dr Gerald Chan and Morningside to GBL. We particularly welcome the depth of experience that Gerald and Morningside bring to our successful commercialization programme in China, which is a key focus for the company, as well as their experience of nurturing successful global technology companies."
Gerald Chan co-founded Morningside in 1986. As a privately-held investment group, Morningside is active in both private equity and venture capital investments in North America, Europe and Asia. The group began its China investments in 1992 and remains active in China's internet, media and life science sectors.
Dr. Chan is currently a board member of Hang Lung Group and servesontheboards ofseveralprivatebiotechnology companies including Serica, Inc., Critical Biologics Corporation, CellCentric, Ltd., Inimex Pharmaceuticals, Inc.,Stealth Peptides Inc., and Vaccine Technologies Inc. Dr. Chan sits on the Science Advisory Council of UCLA, the Global Advisory Committee of the International Society for Stem Cell Research, the advisory board of John Hopkins University - Nanjing University Center for Chinese and American Studies and is a trustee of Fudan University in Shanghai. He received his BS and MS degrees in Engineering from UCLA and a master's degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana Farber Cancer Institute.
23.02.09
Professor David Jones joins GBL as a Scientific Advisor
Green Biologics Ltd (GBL) has appointed Professor David Jones as Scientific Advisor. David is a world leading expert on solventogenic Clostridia and their industrial application for the production of acetone, butanol and ethanol (ABE).
David has retired after a distinguished academic career with the Department of Microbiology, University of Cape Town, South Africa, and more recently, the Department of Microbiology, University of Otago, New Zealand. He has published numerous articles on topics related to Clostridial taxonomy and phylogeny. In addition, David has spent over 40 years supporting the commercial ABE process in South Africa and written numerous review articles on the ABE process.
Dr Edward Green, founder and CTO of GBL, comments: "David is the world's foremost expert in solventogenic Clostridia and their use in the ABE process. David bridges the gap between academic research and industrial fermentation at commercial scale and provides a unique perspective on how best to steer research and development programmes towards commercial deployment. He will be invaluable as we transition from pilot to commercial scale.
archive
